SOLID BIOSCIENCES INC
SLDBNASDAQTrading Snapshot
- Day Range
- $8.72 – $8.96
- 52-Week Range
- $3.79 – $11.45
- Volume
- $2.15B
- Avg Volume
- $1.61B
- Shares Outstanding
- 98.5M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $16M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 60.4x
- EPS (TTM)
- $-1.91
- Dividend Yield
- —
Why Investors Own SLDB
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SOLID BIOSCIENCES INC
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Solid Biosciences Q2 EPS $(0.38) Beats $(0.46) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 9.52 percent increase over losses of $(0.42) per share from
Solid Biosciences Files Prospectus To Offer Up To $200M In Common Stock
-SEC Filing
Solid Biosciences Files Prospectus For Mixed Shelf Offering; Size Not Disclosed
https://www.sec.gov/Archives/edgar/data/1707502/000119312526338410/d360115d424b5.htm